<DOC>
	<DOCNO>NCT02903537</DOCNO>
	<brief_summary>The purpose study determine safety tolerability intranodal administration autologous monocyte-derived dendritic cell tolerised Vitamin-D3 pulse myelin peptide ( tolDC-VitD3 ) multiple sclerosis patient . To select appropriate regime development future therapeutic trial . To evaluate preliminary proof concept clinical and/or radiological activity immunological marker .</brief_summary>
	<brief_title>Tolerogenic Dendritic Cells Therapeutic Strategy Treatment Multiple Sclerosis Patients ( TOLERVIT-MS )</brief_title>
	<detailed_description>Phase I dose ascend ( `` best five '' ) clinical trial . First group start intranodal injection cervical lymph node 5*10^6 tolDC-VitD3 . Up titration depend security outcomes 10*10^6 tolDC-VitD3 , route second cohort dose next uptitration 15*10^6 tolDC-VitD3 . Six cycle per patient follow schema : first four cycle administration 2 week , remain 2 cycle administration 4 week . A last cohort dose identify previous group , administer patient treat beta interferon , route , dose schema .</detailed_description>
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Multiple Sclerosis , Chronic Progressive</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-beta</mesh_term>
	<mesh_term>Cholecalciferol</mesh_term>
	<criteria>1 . EDSS 0.0 6.5 . 2 . Multiple Sclerosis accord 2010 revised Mc Donald criterion , less 15 year evolution disease . 3 . Patients : Active relapse remit multiple sclerosis ( RRMS ) ( 1 relapse last year and/or occurrence â‰¥3 new T2 lesion Gd positive ) wish treat current therapy . Low activity RRMS ( 1 relapse last year occurrence 1 2 T2 lesion Gd positive ) without treatment . Progressive form MS activity ( least 1 relapse last year occurrence 1 2 T2 lesion Gd positive ) . RRMS treat interferon beta ( Additional group ) 4 . T cell proliferation pool myelin peptide induce immune tolerance : Myelin basic protein ( MBP ) 1332 , MBP8399 , MBP111129 , MBP146170 , proteolipid protein ( PLP ) 139154 , Myelin oligodendrocyte glycoprotein ( MOG ) 120 , MOG35 55 ) . 5 . Adequate peripheral venous access . 6 . Signed informed consent . 1 . Use corticosteroid prior 4 week . 2 . Use interferon beta patient retire inefficiency cause glatiramer acetate 4 week prior . 3 . Use fingolimod , dimethylfumarate , natalizumab , immunoglobulins plasmapheresis 12 week ; teriflunomide 15 week prior . 4 . Use azathioprine , mitoxantrone , rituximab , methotrexate , cyclophosphamide , cyclosporine , alemtuzumab immunosuppressive drug , except corticosteroid , time . 5 . Bone marrow stem cell transplant time . 6 . Relapse month prior start treatment . If appear patient meet eligibility criterion , must wait long enough end 30 day free relapse . If corticosteroid administer , MRI perform period consider , new MRI perform 4 week administration corticosteroid . 7 . Pregnancy plan pregnancy within next 12 month breastfeed . 8 . Fertile patient use appropriate method contraception . If patient menopausal sterile must document medical record . 9 . Abusing drug alcohol . 10 . Inability undergo MRI evaluation . 11 . Seropositivity HIV , hepatitis B C and/or syphilis . 12 . History oncological disease . 13 . Clinically relevant concomitant disease : cardiac , pulmonary , neurological , renal major illness . 14 . Splenectomy . 15 . Dementia , psychiatric problem comorbidities might interfere protocol compliance . 16 . To participate another clinical study participate one last 3 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Multiple Sclerosis</keyword>
	<keyword>Dendritic Cells</keyword>
	<keyword>Immune Tolerance</keyword>
	<keyword>Myelin Proteins</keyword>
	<keyword>Tolerogenic dendritic cell</keyword>
</DOC>